Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
Advertisement
Scientific Reports volume 13, Article number: 778 (2023)
1311
13
Metrics details
Obstructive Sleep Apnea (OSA) is related to repeated upper airway collapse, intermittent hypoxia, and intestinal barrier dysfunction. The resulting damage to the intestinal barrier may affect or be affected by the intestinal microbiota. A prospective case–control was used, including 48 subjects from Sleep Medicine Center of Nanfang Hospital. Sleep apnea was diagnosed by overnight polysomnography. Fecal samples and blood samples were collected from subjects to detect fecal microbiome composition (by 16S rDNA gene amplification and sequencing) and intestinal barrier biomarkers—intestinal fatty acid-binding protein (I-FABP) and D-lactic acid (D-LA) (by ELISA and colorimetry, respectively). Plasma D-LA and I-FABP were significantly elevated in patients with OSA. The severity of OSA was related to differences in the structure and composition of the fecal microbiome. Enriched Fusobacterium, Megamonas, Lachnospiraceae_UCG_006, and reduced Anaerostipes was found in patients with severe OSA. Enriched Ruminococcus_2, Lachnoclostridium, Lachnospiraceae_UCG_006, and Alloprevotella was found in patients with high intestinal barrier biomarkers. Lachnoclostridium and Lachnospiraceae_UCG_006 were the common dominant bacteria of OSA and intestinal barrier damage. Fusobacterium and Peptoclostridium was independently associated with apnea–hypopnea index (AHI). The dominant genera of severe OSA were also related to glucose, lipid, neutrophils, monocytes and BMI. Network analysis identified links between the fecal microbiome, intestinal barrier biomarkers, and AHI. The study confirms that changes in the intestinal microbiota are associated with intestinal barrier biomarkers among patients in OSA. These changes may play a pathophysiological role in the systemic inflammation and metabolic comorbidities associated with OSA, leading to multi-organ morbidity of OSA.
Obstructive sleep apnea (OSA) is a common type of sleep breathing disorder, mainly manifested as repeated collapse of the upper airway and cessation of airflow during sleep, leading to intermittent hypoxia (IH) and sleep fragmentation (SF)1,2. OSA afflicts nearly 1 billion people worldwide, with the most significant number in China, followed by the United States and Brazil3. It is a complex condition with evidence of end-organ morbidity and multi-system dysfunction4. However, the pathophysiological mechanism of multiple organ diseases caused by OSA remains unclear. Hereditary and environmental factors are closely related to the inherent phenotypic variation of OSA5. However, they account for only a tiny fraction of the phenotypic differences in OSA. The fecal microbiome is the largest genome in the human body. Its disorders are associated with multi-system diseases such as asthma, allergies, obesity, diabetes, inflammatory bowel disease, cardiovascular disease, and increased all-cause mortality6,7,8. The fecal microbiome may also play an essential role in OSA and OSA-induced multi-organ diseases. Alteration in the gut microbiota has been reported in animal models simulating OSA. In the rat model, intestinal microflora imbalance was involved in the occurrence of OSA- induced hypertension9. Xue et al. investigated the potential role of OSA-induced intestinal microbiota alterations in atherosclerosis development10. However, few studies have directly investigated the gut microbiota in patients with OSA. Only one adult clinical study found that patients with OSA had intestinal flora disturbance11. The newer study proposed that some neurological symptoms may be related to gut dysbiosis12. Also, changes in the intestinal microbiota can cause circadian clock disturbances, leading to metabolic disorders13. Therefore, changes in the intestinal microbiota, in turn, will mediate changes in the host phenotype that manifest as terminal organ disease.
At present, more studies have found that hypoxia is associated with the existence of certain links, such as in the presence of ischemia, hypoxia-induced intestinal dysfunction, the intestinal mucosa epithelium often necrosis, detachment14,15. In particular, the disorder is caused by the influence of low oxygen environment factors, and the intensity of free radical reaction increases with the altitude of the plateau, once the intestinal mucosa is damaged, it will make the intestinal flora planted on it inevitably disorder16. Lavie found that oxidative stress upregulated HIF-1α and decreased the expression of epithelial tight junction protein in the duodenum, altering the permeability of the intestinal barrier, Hypoxia can induce inflammation, and tissues with inflammatory responses often exacerbate hypoxia, a positive feedback phenomenon17. It was found that as the duration of intermittent hypoxia increased, the intestinal mucosa was severely damaged and permeability increased, and this study has reported that intestinal flora displacement can exacerbate structural damage to mesenteric lymph nodes, which in turn increases the level of oxidative stress18.
Alterations in intestinal microbiota accompanied by the destruction of the intestinal barrier are another important factor leading to the escalation of systemic inflammation, metabolic disorders19,20, and multiple organ failure21. The intestinal tract is a microbial-host interface to restrict the escape of intestinal bacteria and toxic media from the intestinal tract. D-lactic acid (D-LA) is the product of the fermentation of gastrointestinal bacteria and served as an indicator of bacterial translocation22, intestinal injury, and intestinal permeability23. Intestinal fatty acid-binding protein (I-FABP) is a recognized blood marker for early epithelial damage. After an attack of acute intestinal ischemia, inflammation, and hypoxia, this level raised rapidly19,24. Plasmatic D-LA and I-FABP are considered to be the most promising and reasonable biomarkers for intestinal barrier impairment19,25. Studies of OSA, both in adults11 and children26, have also shown that these patients have severe intestinal microbiota imbalance. However, evidence from human research linking the microbiome to intestinal barrier dysfunction in OSA is lacking.
Therefore, we look into the relationship between dysbiotic gut microbiome and impaired gut barrier integrity in OSA patients.
A prospective case–control study was conducted. Patients aged 18–65 years with suspected OSA were enrolled consecutively in this study. All participants were non-vegetarian, traditional Chinese food. Fecal samples and fasting venous blood were collected the following morning after polysomnography (PSG). No subjects suffered from cardiovascular, cerebrovascular, malignant tumors, respiratory system, hematological system, digestive tract, kidney, or thyroid disease, and no one received continuous positive airway pressure (CPAP) treatment. None of the participants had received antibiotics or microbial modifiers in the two months before enrolment, and none had undergone surgery. The study approval was obtained from the ethics committee of Nanfang Hospital (NFEC No. 2019-091) with the informed consent of each participant.
All subjects used the standard PSG for one night, including electroencephalography, electrooculogram, electromyogram, and electrocardiogram. Technologists conducted PSG from 10 p.m. to 7 a.m. Trained Sleep Physician manually scored the PSG data based on the American Academy of Sleep Medicine Guidelines27. AHI was summed up times of apnea episodes per hour (airflow decreased ≥ 90% from baseline for at least 10 s) and hypopnea episodes per hour (airflow decreased ≥ 50% for at least 10 s and finger pulse oxygen saturation decreased ≥ 3%). All participants were divided into four groups according to their AHI score: No OSA (AHI < 5 times/hour), mild OSA (5 ≤ AHI < 15 times/hour), moderate OSA (15 ≤ AHI < 30 times/hour), and severe OSA (AHI ≥ 30 times/hour)28.
After nearly 12 h of fasting (from 8p.m. to 8 a.m. the next day), 1 g of fresh fecal samples were collected in a sterile fecal tube and stored in a refrigerator at -80 °C for subsequent analysis, and fasting venous blood was obtained from 7 a.m. to 8 a.m. after PSG. Two ml of them was collected with a heparin anticoagulant tube, then was centrifuged (3500 × g, 4 °C, 10 min), separated, and stored at − 80 °C for subsequent intestinal barrier function analysis. Other blood indexes such as lipid, glucose were measured by automatic biochemical analyzer (Beckman AU5431, USA). Blood routine was performed using resistance method (Coulter principle) by hematology analyzer (UniCel DxH800, USA).
The inclusion and exclusion criteria were shown as follows:
Inclusion: Patients aged 18–65 years with suspected OSA; non-vegetarian; traditional Chinese food.
Exclusion: having suffered from cardiovascular, cerebrovascular, malignant tumors, respiratory system, hematological system, digestive tract, kidney, or thyroid disease; having received continuous positive airway pressure (CPAP) treatment; having received antibiotics or microbial modifiers in the two months before enrolment, having undergone surgery.
I-FABP and D-LA plasma levels were measured by high-sensitivity ELISA (Quantikine; USA; catalog number DFBP20) and Colorimetric Assay (BioVision; USA; catalog number K667) according to product instructions. The detection limits of I-FABP and D-LA were 2.12 pg/mL and 0.01 mM, respectively.
Bead beating isolation was done to extract genomic DNA using the QIAamp DNA Kit (QIAGEN, Hilden, Germany), following the manufacturer’s protocol. The extracted DNA concentration was measured by Qubit 2.0 Fluorometer (Life Technology, Carlsbad, CA). DNA quality was detected by 1.0% agarose gel electrophoresis. Then, the 16S rDNA gene regions (V3 and V4) were amplified by PCR. The 16S rDNA libraries were sequenced on the Illumina MiSeq platform PE300 mode (Illumina, USA) using a V3 reagent kit with a 250 bp paired-end run. Sequences were aggregated into operational taxonomic units (OTUs) using 97% identity of the Silva v128 database29.
Quantitative data were displayed by mean ± standard deviation or median (interquartile range) and comparison by Wilcox or Kruskal–Wallis rank-sum test or Mann–Whitney or ANOVA. Qualitative data were displayed by quantity (rates) and comparison by Chi-square test or Fisher’s exact test. Spearman or Pearson correlation tests were utilized to evaluate correlation with continuous variables. Based on 16S data, Alpha(α) diversity index (Observed OTU richness and Shannon Diversity) and Beta(β) diversity index based on Principal Coordinate Analysis (PCoA) (unweighted-Unifrac distance, Adonis) was used to assess the differences between groups. Linear discriminant analysis (LDA) and LDA effect size (LEfSe) (LEfSe 1.0) was used to assess the taxonomic differences among groups. Multiple regression was used to analyze the relationship between clinical variables (such as gender, age, BMI, AHI) and the microbiota characteristics identified in the severe OSA group. The network was then utilized to present the relationship between fecal microbiome, intestinal barrier biomarkers, and AHI (Cytoscape_v3.9.1). Statistical analysis of data was conducted in SPSS (version 21.0) and R software (v3.5.1). P < 0.05 indicates that the difference was statistically significant.
The approval was obtained from the ethics committee of Nanfang Hospital (NFEC No.2019-091). The procedures used in this study adhere to the tenets of the Declaration of Helsinki. Informed consent was obtained from each participant in the study.
A total of 193 patients were screened from May 2019 to November 2019 in our sleep center, and 48 were eventually included in the analysis (Fig. 1). The prevalence of OSA was high (37/48 patients; 77%) in our sleep center, and 31% of participants were severe OSA. OSA was positively correlated with males, AHI, and BMI, and negatively correlated with SaO2. Levels of intestinal barrier markers were greater among different OSA categories than the control subjects (P ≤ 0.01), except for the I-FABP in the mild group. Levels of D-LA were significantly related to I-FABP (Spearman rho = 0.429, p = 0.002). But there were no significant differences in age, hypertension, or diabetes (Table 1).
Patient flow chart.
A total of 3980179 paired-end reads were attained, with an average of 117491 nonchimera tags and an average of 421 OTUs per sample. Heat map based on the fecal samples of most abundant taxa at the genus level showed gut microbiota had a high relative abundance of Bacteroides, Faecalibacterium, Blautia, and Lachnospira in most samples (Fig. 2).
Heatmap of 48 stool samples at the genus level. Stool samples demonstrate the high relative abundance of Bacteroides, Faecalibacterium, Blautia, Blautia, and Lachnospira(relative abundance ≥ 0.5% were annotated, < 0.5% were classified as others).
Then, we assessed differences in the fecal microbiome between the participants with various degrees of OSA severity compared with no OSA. α diversity analysis showed no differences in Observed OTU richness and Shannon diversity index between control subjects and OSA (Supplementary Figure S1). Other species diversity indices (Simpson) and richness (ACE, Chao) were also not statistically significant (Supplementary Table S1). β diversity analysis based on PCoA showed significant differences in the composition of OSA with varying severity (Fig. 3A; Adonis p = 0.044). Further pairwise analysis (OSA group with different severity compared with no OSA group) showed that the microbiome characteristics of severe OSA subjects were significantly separated from those of no OSA (Fig. 3B; Adonis p = 0.008). Simultaneously, differences in the other OSA and no OSA groups were similar (Supplementary Figure S2). Unweighted uniFrac distance was an indicator of the degree of compositional similarity between samples. The closer the samples were, the more similar the samples’ species composition was, and vice versa.
β diversity differences in different severity groups of OSA and severe OSA. PCOA (Unweigther-Unifrac distance) between (A) different severity groups of OSA versus no OSA (Adonis P = 0.044) and (B) severe OSA versus no OSA (adonis P = 0.005).
To identify taxa differences of the gut bacteria, LDA and LEfSe were used. The gut microbiota on the top four genera from different severity of OSA subjects was enriched with Fusobacterium, Lachnoclostridium and decreased with Ruminococcaceae_UCG_013 when compared to no OSA subjects (Fig. 4A, Supplementary Figure S3A). The microbiota of patients with severe OSA was enriched with Fusobacterium, Megamonas, Lachnospiraceae_UCG_006 and decreased with Anaerostipes (Fig. 4B, Supplementary Figure S3B). The mild group was enriched with Turicibacter and Lachnoclostridium, decreased with Holdemanelle and Enterococcus (Fig. 4C, Supplementary Figure S3C). While in moderate OSA was increased with Fusobacterium, Megamonas, and Lachnoclostridium, decreased with Eubacterium_rectale_group (Fig. 4D, Supplementary Figure S3D). The top four genera’s taxa with relative abundance greater than 0.5% in all samples among severe OSA were further analyzed by a Scatter plot of relative abundance (Fig. 4E). At the phylum level, Fusobacteria showed significant differences among the four groups (P = 0.0173). However, Firmicutes, Bacteroides, Actinobacteria, and Proteobacteria had no significant differences (Supplementary Table S2, nor did the Firmicutes (F) to Bacteroides(B) ratio (Supplementary Figure S4).
Taxa differences in different severity OSA. LEfSe identifies microbiota differences in (A) Different severity groups of OSA versus no OSA (Kruskal–Wallis), (B) severe OSA versus no OSA (Wilcox). (C) Mild OSA versus no OSA(Wilcox). (D) moderate OSA versus no OSA (Wilcox). (E) Scatter plot of the bacteria at the genus level with relative abundance greater than 0.5% in all samples in severe OSA participants (Wilcox).
To estimate the potential relationship between clinical variables and the microbiota characteristics with relative abundance greater than 0.5% in all samples of severe OSA, we conducted Spearman analysis. Significant associations between microbiota characteristics and AHI, SaO2, BMI, glucose, TG, TCHO, HDL, LDL and gut epithelial barrier markers were found. The D-LA level was positively correlated with the abundance of Lachnoclostridium, Megamonas and Fusobacterium, and negatively correlated with Peptoclostridium and Anaerostipes (Table 2). While I-FABP level was negatively correlated with Peptoclostridium. In addition, Peptoclostridium was significantly correlated with Neutrophils and Monocytes (Table 2). To further explore the independent relationship between severe OSA and the microbiota characteristics mentioned above, we conducted multiple linear regression analysis. Significant association with severe OSA was identified. Higher AHI predicted higher relative abundance of Fusobacterium (B = 0.538, P = 0.041) and Peptoclostridium (B = − 0.491, P = 0.046), independent of age, BMI, and sex (Table 3).
To investigate the possible relationship between intestinal barrier dysfunction and intestinal microbiota dysfunction, we evaluated the association of changes in gut microbes with high and low values of intestinal barrier biomarkers. High and low D-LA and I-FABP subgroups were defined. The high biomarker subgroup has the biomarker value in the fourth quartile (highest 25%) and low biomarker subgroup has the value in the third quartile (0–75%). PCoA based on Unweighted-Unifrac had a significant difference in the composition of intestinal flora with high and low D-LA (Fig. 5A; Adonis P = 0.049), while there was no difference in α diversity (Supplementary Figure S5). There was no difference in both α and β diversity among I-FABP groups (Supplementary Figure S5B, Fig. 5B). LEfSe analysis showed differentially enriched taxa between groups. Samples with high D-LA were enriched with Ruminococcus_2, Lachnoclostridium, and Lachnospiraceae_UCG_006 and decreased in Senegalimascilia (Fig. 5C). Samples with high I-FABP were enriched with Alloprevotelle (Fig. 5D). Therefore, this study demonstrated a relationship between the enrichment of intestinal microbiota and the intestinal barrier in OSA.
Correlation between changes in intestinal microbiota and intestinal barrier dysfunction. Beta diversity between (A) high versus low D-LA (Adonis p = 0.049) and (B) high versus low I-FABP levels (Adonis p = ns). (C) The gut microbiota with high D-LA was enriched with Ruminococcus_2, Lachnoclostridium, and Lachnospiraceae_UCG_006 and decreased with Senegalimascilia (Wilcox). (D) The gut microbiota with high I-FABP was enriched with Alloprevotella (Wilcox).
To further explore the relationship of gut microbiota, intestinal barrier, and AHI, we built a co-occurrence network at the genus level (> relative abundance 0.5% species). The graph represented features that were positively correlated. Network analysis identified the taxa of defined meta-communities that tend to coexist in the gut microbiota. One metacommunity was characterized by co-occurrence between Ruminococaceae_NK4A214_group, Olsenella, Ruminococcaceae_UCG_014, and Alloprevotella. AHI, D-LA, and I-FABP were associated with unique intestinal flora, respectively. Streptobacillus, Prevotellaceae_UCG_003, and Rikenellaceae_RC9_gut_group were the mutual genera of the three (Fig. 6). Thus, supporting that intestinal microbiota was related to OSA and intestinal barrier.
Network between taxa, AHI, and intestinal barrier biomarkers. SparCC was used to construct a genus taxa network. Positively related variables were kept in the network (The correlation coefficient between bacteria and clinical indicators was ≥ 0.4, and between bacteria and bacteria was ≥ 0.7). AHI, D-.LA, and I-FABP were associated with unique taxa. Streptobacillus, Prevotellaceae_UCG_003, and Rikenellaceae_RC9_gut_group were the common genera. Gut commensals co-occurred AHI and intestinal barrier biomarkers (D-LA and I-FABP).
In addition, the co-occurrence network between intestinal barrier, AHI and microbiome in different severity levels (mild/moderate/severe OSA) was shown in Supplementary Fig. S6. The chart shows that in mild OSA, Megamonas, Peptoclostridium and Senegalimassilia are the three reciprocal genera (Supplementary Figure S6A); in moderate OSA, Alloprevotella is the three reciprocal genera (Supplementary Figure S6B). In the severe OSA, Lachnospiraceae_UCG_001, Ruminiclostridium_6 and Eubacterium_xylanophilum_group were three intergeneric genera (Supplementary Figure S6C). The severity co-occur with the different species genera, which deserves further studies to follow.
OSA is a systemic, comprehensive disease with cardiovascular disease and metabolic abnormalities. IH plays an important role in OSA and its associated multi-organ pathology, but its mechanism of action is not fully understood. This study confirmed that changes in the gut microbiome were associated with gut barrier biomarkers in patients with OSA, and that the dominant genera of severe OSA were also associated with glucose, lipids, neutrophils, monocytes and BMI. Network analysis identified associations between the gut microbiome, gut barrier biomarkers, and AHI. These changes may play a pathophysiological role in the systemic inflammation and metabolic comorbidities associated with OSA, leading to the multi-organ morbidity of OSA.
The present investigation found an association between OSA and increased intestinal barrier biomarkers that are also associated with unique microbiome profiles, with D-LA levels positively correlated with Lachnoclostridium, Megamonas, and Fusobacterium and negatively correlated with Peptoclostridium and Anaerostipes. I-FABP levels were negatively correlated with Peptoclostridium. β-Diversity showed significant differences in microbial community composition between high and low D-LA groups, with high plasma D-LA positively correlated with Ruminococcus_2, Lachnoclostridium, Lachnospiraceae_UCG_006 positively and Senegalimascilia negatively, whereas fecal microbiota high in I-FABP were enriched in Alloprevotella. This suggests that impairment of the epithelial barrier is associated with enrichment in specific microbiota. Increased intestinal barrier alterations in OSA have been well described, such as circulating blood I-FABP, D-LA and lipopolysaccharide-binding protein are increased23,30,31. We previously reported that circulating D-LA and I-FABP are significantly elevated in OSA compared with healthy subjects19.
Based on our present study and reports in the relevant literature, we speculate that repeated hypoxia may be a cause of epithelial damage that can lead to dysbiosis of the intestinal flora, and that these adverse factors may impair intestinal function by increasing intestinal permeability. Repeated hypoxia is responsible for epithelial damage that can lead to gut dysbiosis. Recurrent hypoxia and reoxygenation could impair intestinal function by increasing intestinal permeability, bacterial translocation, and decreasing the integrity of tight junctions25,26. Increased gut barrier alterations in OSA have been well described, such as increased I-FABP, D-LA, and Lipopolysaccharide-Binding Protein in circulation blood18,27,28. A mouse model of sleep apnea had shown that intestinal colonization by Prevotella and Desulfovibrio contributed to increased intestinal permeability29. In humans, D-lactate producing bacteria, such as Streptococcus and Enterococcus, have been found in faces of patients with chronic fatigue syndrome12. Furthermore, the significant increase in intestinal bacterial translocation products (endotoxin and D-lactic acid) was associated with systemic inflammation and could predict adverse cardiovascular events30. We previously reported that circulating D-LA and I-FABP were significantly elevated in OSA compared to healthy subjects14. This survey also found a relationship between OSA and an increase in gut barrier biomarkers. These biomarkers were also related to unique microbiome profiles. D-LA level was positively correlated with Lachnoclostridium, Megamonas and Fusobacterium, and negatively correlated with Peptoclostridium and Anaerostipes. The level of I-FABP was negatively correlated with Peptoclostridium. The β-diversity showed a significant difference in microbial community composition between high and low D-LA groups. High plasma D-LA was positively correlated with Ruminococcus_2, Lachnoclostridium, Lachnospiraceae_UCG_006, and negative with Senegalimascilia, while the microbiota of fecal with high I-FABP was enriched with Alloprevotella. It indicated that the damaged epithelial barrier was related to the enrichment of specific microbiota. Fusobacterium and Lachnoclostridium are both differential bacteria, which were confirmed again in both DESeq and LEFse methods.
In addition, hypoxia has a direct effect on intestinal gut dysbiosis. Morenos-Indias et al. found significant changes in intestinal microbial community structure in an animal model mimicking OSA32. IH exposed in mice models cumulatively disrupted the fecal microbiome and metabolism33. These animal models, analogous to those of chronic OSA, showed an alteration in the gut microbiota compared to normal level of oxygen. In humans, an increased intestinal oxygen level also affects the composition of fecal and mucosal adherent microbiota (e.g., Proteobacteria and Actinobacteria)30. Repeated hypoxia due to upper airway obstruction can also have local manifestations in all blood perfused organs34. Therefore, microbiome changes may occur in different mucous membranes in OSA. For example, alterations in the nasal microbiome are related to OSA and inflammatory biomarkers35. Lung microbiota in OSA is distinct from that of control subjects36. Oral microbiota is significantly disturbed in pediatric patients with OSA, leading to OSA-related metabolomics37. IH and SF, two essential characteristics of OSA, also established a hypoxic environment in many parts of the digestive tract38. Albenberg et al. observed that oxygenation of the host influences gut luminal oxygenation, altered the composition of the gut microbiology30. Reduced oxygen in the intestine enabled obligate anaerobic microorganisms(such as Proteobacteria and Actinobacteria) to become more competitive and overgrowth30. Simultaneously, increased tissue oxygenation can directly affect microorganisms, such as reducing anaerobes39. Therefore, the gut may provide a unique environment conducive to living aerobic and facultative anaerobic organisms.
In our study, OSA was related to alterations in β-diversity of the fecal microbiome. Among OSA subjects with different degrees of severity, the intestinal flora of Fusobacterium and Lachnoclostridium were enriched, while Ruminococcaceae_UCG_013 was reduced compared to no OSA. In severe OSA, Fusobacterium, Megamonas, and Lachnospiraceae_UCG_006 were abundant, while Ruminococcaceae_UCG_013 was reduced. It was consistent with Ko C. et al., the relative abundance of the Ruminococcaceae was greater in the control group11. While the relative abundances in Megamonas were contrary to Ko C. et al. This may be due to different DNA extraction kits, different PCR amplification primers and clustering methods, or the participants ‘ living areas and lifestyles are different, or our samples are relatively small. However, not only did we find an enrichment of Megamonas in the severe group, but also an increase in the moderate group. In contrast, Ko C. et al. only found a decrease in Megamonas in the severe group. Future clinical studies are needed to validate our results. Then, Fusobacterium and Peptoclostridium demonstrated an independent relationship with severe OSA, which may be useful in identifying subjects at risk of gut microbiome disorders related to OSA. Some of the above fecal microbiome differences, such as Lachnoclostridium and Lachnospiraceae_UCG_006, were also associated with intestinal barrier biomarkers. Moreover, the differences in microbiota signatures of the moderate group were very close to those of the severe group. Thus, it supported the reasonableness of comparing the moderate and severe OSA groups as a single OSA group with the no OSA group, without including the mild group in the study40.
In addition, microbiota characteristics in severe OSA was not only significantly correlated with sleep parameters, but also associated with lipids and BMI. Anaerostipes was correlated with fasting blood glucose and Peptoclostridium was associated with neutrophils and monocytes. Therefore, alterations of these microbiota could cause low-grade chronic inflammation41, immune and metabolic abnormalities. Fusobacterium has been linked to cardiovascular disease42, colorectal cancer43, oral and lung infections44,45. Megamonas is correlated with chronic kidney disease46. Alloprevotella has been associated with infection and diabetes47,48. Thus, Changes in these microbes may play an important role in multi-system and multi-organ disease triggered by OSA. Our study also found that the microbiota characteristics in the severe OSA group were significantly correlated with the intestinal barrier biomarkers. The co-occurrence network analysis identified an association between the fecal microbiome, intestinal barrier biomarkers, and AHI. These results suggested that intestinal barrier dysfunction was associated with bacterial dysfunction in OSA.
Recently, Mashaqi S, in his review of OSA and gut dysbiosis, found that most studies were conducted in animal models with an increase in the F/ B ratio41. Also, among children, the ratio of F/B was higher in snorers than in controls26. Unlike previous animal models and children’s studies, we did not find significant differences in α diversity or F/B proportion among patients with OSA. However, our results are consistent with another adult OSA study11. This may be because humans and animals have different gut populations. Collado et al. enrolled snoring children through a questionnaire, did not perform PSG test, which lacked the ability to diagnose snoring or OSA in children without this test. Furthermore, children’s intestine may not be fully developed49, and their dietary structure and tolerance to hypoxia may differ from adults’. More studies on the intestinal flora of adult OSA are needed in the future to support our findings.
The advantages of this study include not only clinical evaluation of the relationship between intestinal microbiota and OSA but also novel evaluation of the association with haemoconcentration of D-LA and I-FABP. We supported the pathophysiological role of intestinal flora and changes in the intestinal barrier in OSA. However, there are some disadvantages. The first disadvantage is that the included sample size is relatively small. Although the intestinal flora in OSA was statistically significantly different from no OSA, no differences in α and β diversity were observed in mild and moderate OSA. Second, we did not collect detailed dietary habits of participants and their physical activity that might affect the gut microbiome50,51. Third, we focused on the most important sleep parameters, other sleep indicators such as sleep stages and sleep efficiency were not included, and these needs to be taken into account in the future. In addition, we did not evaluate the effects of microbiota modification strategies (e.g., CPAP, microecological modulators) on intestinal barrier biomarkers and intestinal microbiota. Future study may require more longitudinal, interventional investigations to assess causality. With the important role of precision medicine in the development of individualized disease treatment protocols. The approach of gut microbial composition and metabolic components will also become an important part of the individualized treatment of OSA. The present study provides a scientific basis for the involvement of intestinal flora in OSA and pathogenesis, and how OSA regulates host metabolism through intestinal flora will be worthy of further study, and there are few reports of related clinical studies at home and abroad. For this reason, further studies in multicenter and large sample clinical trials are needed in the future.
In this study, we used human specimens to construct a model to further demonstrate that OSA can cause significant alterations in the structure of the intestinal flora, thereby changing the homeostatic relationship between host and intestinal flora, and ultimately can even lead to multi-organ damage as well as disease. This finding may provide clinical opportunities to develop targeted therapies for patient-specific microbiota profiles.
The datasets discussed during the current study are deposited in NCBI’s Sequence Read Archive (SRA) and are accessible through SRA Series accession number PRJNA851918. Other datasets generated or analysed during this study are included in this published article and its supplementary information files.
Young, T., Peppard, P. E. & Gottlieb, D. J. Epidemiology of obstructive sleep apnea: A population health perspective. Am. J. Respir. Crit. Care Med. 165(9), 1217–1239 (2002).
Article Google Scholar
Douglas, N. J. & Polo, O. Pathogenesis of obstructive sleep apnoea/hypopnoea syndrome. Lancet 344(8923), 653–655 (1994).
Article CAS Google Scholar
Benjafield, A. V. et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: A literature-based analysis. Lancet Respir. Med. 7(8), 687–698 (2019).
Article Google Scholar
Farré, N., Farré, R. & Gozal, D. Sleep apnea morbidity. Chest 154(4), 754–759 (2018).
Article Google Scholar
Riha, R. L., Gislasson, T. & Diefenbach, K. The phenotype and genotype of adult obstructive sleep apnoea/hypopnoea syndrome. Eur. Respir. J. 33(3), 646–655 (2009).
Article CAS Google Scholar
Carmen Collado, M., Rautava, S., Isolauri, E. & Salminen, S. Gut microbiota: A source of novel tools to reduce the risk of human disease?. Pediatr. Res. 77(12), 182–188 (2015).
Article Google Scholar
Everard, A. & Cani, P. D. Diabetes, obesity and gut microbiota. Best Pract. Res. Clin. Gastroenterol. 27(1), 73–83 (2013).
Article CAS Google Scholar
Heianza, Y., Ma, W., Manson, J. E., Rexrode, K. M. & Qi, L. Gut microbiota metabolites and risk of major adverse cardiovascular disease events and death: A systematic review and meta-analysis of prospective studies. J. Am. Heart Assoc. 6, e0049477 (2017).
Article Google Scholar
Durgan, D. J. et al. Role of the gut microbiome in obstructive sleep apnea-induced hypertension. Hypertension 67(2), 469–474 (2016).
Article CAS Google Scholar
Xue, J. et al. Intermittent hypoxia and hypercapnia accelerate atherosclerosis, partially via trimethylamine-oxide. Am. J. Respir. Cell Mol. Biol. 57(5), 581–588 (2017).
Article CAS Google Scholar
Ko, C. et al. Gut microbiota in obstructive sleep apnea–hypopnea syndrome: Disease-related dysbiosis and metabolic comorbidities. Clin. Sci. 133(7), 905–917 (2019).
Article CAS Google Scholar
Sheedy, J. R. et al. Increased d-lactic acid intestinal bacteria in patients with chronic fatigue syndrome. In Vivo 23(4), 621–628 (2009).
CAS Google Scholar
Thaiss, C. A. et al. Transkingdom control of microbiota diurnal oscillations promotes metabolic homeostasis. Cell 159(3), 514–529 (2014).
Article CAS Google Scholar
Luo, H., Guo, P. & Zhou, Q. Q. Role of TLR4/NF-κB in damage to intestinal mucosa barrier function and bacterial translocation in rats exposed to hypoxia. PLoS ONE 7(10), e46291 (2012).
Article ADS CAS Google Scholar
Kayser, B. & Verges, S. Hypoxia, energy balance, and obesity: An update. Obes. Rev. 22(2), 1 (2021).
Google Scholar
Zhang, J. H. et al. Plateau hypoxia attenuates the metabolic activity of intestinal flora to enhance the bioavailability of nifedipine. Drug Deliv. 25(1), 1175–1181 (2018).
Article CAS Google Scholar
Lavie, L. Oxidative stress-A unifying paradigm in obstructive sleep apnea and comorbidities. Prog. Cardiovasc. Dis. 51(4), 303–312 (2009).
Article CAS Google Scholar
Han, N. et al. Hypoxia: The “invisible pusher” of gut microbiota. Front. Microbiol. 12, 690600 (2021).
Article Google Scholar
Li, Q. et al. Impaired intestinal barrier in patients with obstructive sleep apnea. Sleep Breath. 25(2), 749–756 (2021).
Article Google Scholar
Mehra, R. & Teodorescu, M. Sleep, circadian disruption, and microbial-immune interactions. Chest 154(4), 740–742 (2018).
Article Google Scholar
Swank, G. M. & Deitch, E. A. Role of the gut in multiple organ failure: Bacterial translocation and permeability changes. World J. Surg. 20(4), 411–417 (1996).
Article CAS Google Scholar
Clausen, M. R., Bonnén, H., Tvede, M. & Mortensen, P. B. Colonic fermentation to short-chain fatty acids is decreased in antibiotic-associated diarrhea. Gastroenterology 101(6), 1497–1504 (1991).
Article CAS Google Scholar
Heizati, M. et al. Does increased serum d-lactate mean subclinical hyperpermeability of intestinal barrier in middle-aged nonobese males with OSA?. Medicine (Baltimore) 96(49), e9144 (2017).
Article CAS Google Scholar
Derikx, J. P. M., Schellekens, D. H. S. M. & Acosta, S. Serological markers for human intestinal ischemia: A systematic review. Best Pract. Res. Clin. Gastroenterol. 31(1), 69–74 (2017).
Article CAS Google Scholar
Evennett, N. J., Petrov, M. S., Mittal, A. & Windsor, J. A. Systematic review and pooled estimates for the diagnostic accuracy of serological markers for intestinal ischemia. World J. Surg. 33(7), 1374–1383 (2009).
Article Google Scholar
Collado, M. C. et al. Dysbiosis in snoring children. J. Pediatr. Gastr. Nutr. 68(2), 272–277 (2019).
Article Google Scholar
Kapur, V. K. et al. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: An American Academy of sleep medicine clinical practice guideline. J. Clin. Sleep Med. 13(3), 479–504 (2017).
Article Google Scholar
de la Hoz, R. E. et al. Snoring and obstructive sleep apnea among former World Trade Center rescue workers and volunteers. J. Occup. Environ. Med. 52(1), 29–32 (2010).
Article Google Scholar
Quast, C. et al. The SILVA ribosomal RNA gene database project: Improved data processing and web-based tools. Nucleic Acids Res. 41, 590–596 (2013).
Article Google Scholar
Barceló, A. et al. Gut epithelial barrier markers in patients with obstructive sleep apnea. Sleep Med. 26, 12–15 (2016).
Article Google Scholar
Kheirandish-Gozal, L. et al. Lipopolysaccharide-binding protein plasma levels in children: Effects of obstructive sleep apnea and obesity. J. Clin. Endocrinol. Metab. 99(2), 656–663 (2014).
Article CAS Google Scholar
Moreno-Indias, I. et al. Intermittent hypoxia alters gut microbiota diversity in a mouse model of sleep apnoea. Eur. Respir. J. 45(4), 1055–1065 (2015).
Article Google Scholar
Tripathi, A. et al. Intermittent hypoxia and hypercapnia, a hallmark of obstructive sleep apnea, alters the gut microbiome and metabolome. Msystems. 3(3), e18-20 (2018).
Article Google Scholar
Almendros, I. et al. Changes in oxygen partial pressure of brain tissue in an animal model of obstructive apnea. Respir. Res. 11(1), 3 (2010).
Article Google Scholar
Wu, B. G. et al. Severe obstructive sleep apnea is associated with alterations in the nasal microbiome and an increase in inflammation. Am. J. Respir. Crit. Care. 199(1), 99–109 (2019).
Article CAS Google Scholar
Lu, D. et al. Profiling of lung microbiota in the patients with obstructive sleep apnea. Medicine (Baltimore) 97(26), e11175 (2018).
Article Google Scholar
Xu, H. et al. Pediatric obstructive sleep apnea is associated with changes in the oral microbiome and urinary metabolomics profile: A pilot study. J. Clin. Sleep Med. 14(9), 1559–1567 (2018).
Article Google Scholar
Costerton, J. W., Lewandowski, Z., Caldwell, D. E., Korber, D. R. & Lappin-Scott, H. M. Microbial biofilms. Annu. Rev. Microbiol. 49, 711–745 (1995).
Article CAS Google Scholar
Thom, S. R. Hyperbaric oxygen: Its mechanisms and efficacy. Plast. Reconstr. Surg. 127(Suppl 1), 131S-141S (2011).
Article CAS Google Scholar
Yang, W. et al. Oropharyngeal microbiome in obstructive sleep apnea: Decreased diversity and abundance. J. Clin. Sleep Med. 15(12), 1777–1788 (2019).
Article Google Scholar
Mashaqi, S. & Gozal, D. Obstructive sleep apnea and systemic hypertension: Gut dysbiosis as the mediator?. J. Clin. Sleep Med. 15(10), 1517–1527 (2019).
Article Google Scholar
Ford, P. J. et al. Inflammation, heat shock proteins and periodontal pathogens in atherosclerosis: An immunohistologic study. Oral. Microbiol. Immunol. 21(4), 206–211 (2006).
Article CAS Google Scholar
Kostic, A. D. et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 22(2), 292–298 (2012).
Article CAS Google Scholar
Kolenbrander, P. E., Palmer, R. J., Periasamy, S. & Jakubovics, N. S. Oral multispecies biofilm development and the key role of cell-cell distance. Nat. Rev. Microbiol. 8(7), 471–480 (2010).
Article CAS Google Scholar
Bartlett, J. G. Anaerobic bacterial infections of the lung and pleural space. Clin. Infect. Dis. 16(Suppl 4), S248-255 (1993).
Article Google Scholar
Lun, H. et al. Altered gut microbiota and microbial biomarkers associated with chronic kidney disease. Microbiologyopen. 8(4), e678 (2019).
Article CAS Google Scholar
Wu, W. et al. Protective effect of akkermansia muciniphila against immune-mediated liver injury in a mouse model. Front. Microbiol. 8, 1804 (2017).
Article Google Scholar
Wei, X. et al. Xiexin Tang improves the symptom of type 2 diabetic rats by modulation of the gut microbiota. Sci. Rep. 8(1), 3685 (2018).
Article ADS Google Scholar
Giusy, R. et al. Early-life intestine microbiota and lung health in children. J. Immunol. Res. 2017, 1–5 (2017).
Google Scholar
Singh, R. K. et al. Influence of diet on the gut microbiome and implications for human health. J. Transl. Med. 15(1), 73 (2017).
Article Google Scholar
Dorelli, B. et al. Can physical activity influence human gut microbiota composition independently of diet? A systematic review. Nutrients 13, 1890 (2021).
Article CAS Google Scholar
Download references
This work is supported by Guangdong Science and Technology Planning Project (K20206002), Yinzhou Science and Technology Project in the Field of Agriculture and Social Development (2019AS0020),and the Science and Technology Program for Public Welfare of Ningbo, China (2021S175).
Department of Respiratory and Critical Medicine, Ningbo Yinzhou No. 2 Hospital, Ningbo, 315192, Zhejiang Province, China
Qianjun Li, Mingming Wang, Yongquan Dong & Feijie Lu
Sleep Medicine Center, Nanfang Hospital, Southern Medical University, Guangzhou, 510600, China
Qianjun Li, Ting Xu, Danqing Li, Huanyu Tan, Yin Jiang, Qinge Xie, Lijie Feng & Taoping Li
Department of Pulmonary and Critical Care Medicine, Ningbo Medical Center Lihuili Hospital, Ningbo, China
Chuan Shao
Department of Special Procurement Ward, The First Affiliated Hospital of Soochow University, Suzhou, China
Chuan Shao
Department of Cardiovascular, Hangzhouwan Hospital, Ningbo, Zhejiang Province, China
Wenhui Gao
School of Pharmacy, Hangzhou Medical College, Hangzhou, China
Xiumin Wang
Department of High-Throughput, Guangzhou Huayin Health Medical Group Co., Ltd, Guangzhou, China
Fengbo Cai
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
Q.L., T.L., T.X., M.W. contributed substantially to the study design. Q.L., T.L., C.S., W.G., Y.D., X.W., F.L. contributed substantially to data acquisition and analysis. Q.L., T.X., T.L., C.S., W.G., Y.D., X.W., M.W., T.L., F.L. contributed substantially to the data interpretation, manuscript writing and article revision. Q.L., D.L., H.T., Y.J., Q.X., L.F. recruited subjects and collected samples and data. Q.L., T.X., F.C. contributed substantially to conduct experiments and perform biological analysis of 16S data. All authors read and approved the final manuscript for submission. Patients signed informed consent regarding publishing their data and photographs.
Correspondence to Qianjun Li or Taoping Li.
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Reprints and Permissions
Li, Q., Xu, T., Shao, C. et al. Obstructive sleep apnea is related to alterations in fecal microbiome and impaired intestinal barrier function. Sci Rep 13, 778 (2023). https://doi.org/10.1038/s41598-023-27784-0
Download citation
Received: 10 September 2022
Accepted: 09 January 2023
Published: 15 January 2023
DOI: https://doi.org/10.1038/s41598-023-27784-0
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
Advertisement
© 2023 Springer Nature Limited
Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.